Clinical Trials List
2020-11-15 - 2028-12-31
Phase III
Recruiting5
ICD-10C54.1
Malignant neoplasm of endometrium
ICD-10C54.2
Malignant neoplasm of myometrium
ICD-10C54.3
Malignant neoplasm of fundus uteri
ICD-10C54.9
Malignant neoplasm of corpus uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9182.0
Malignant neoplasm of corpus uteri, except isthmus
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yi-Jen Chen Division of Obstetrics & Gynecology
- 胡育文 Division of Radiation Therapy
- 沈書慧 Division of Radiology
- Huann-Cheng Horng Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Cheng-Tao Lin Division of Obstetrics & Gynecology
- Yun-Hsin Tang Division of Obstetrics & Gynecology
- Huei-Jean Huang Division of Obstetrics & Gynecology
- Gigin Lin Division of Radiology
- 陳威君 Division of Obstetrics & Gynecology
- 黃寬仁 Division of Obstetrics & Gynecology
- 吳仁欽 Division of Others
- 容世明 Division of Pediatrics
- 黃彥綾 Division of Radiology
- HSIU-JUNG TUNG Division of Obstetrics & Gynecology
- 周宏學 Division of Obstetrics & Gynecology
- Ting-Chang Chang Division of Obstetrics & Gynecology
- 黃意婷 Division of Hematology & Oncology
- Angel Chao Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25-38 participants
-
Global
990 participants
